2seventy bio Reports Fourth Quarter and Full Year 2024 Financial Results [Yahoo! Finance]
2seventy bio Reports Fourth Quarter and Full Year 2024 Financial Results
2seventy bio, Inc. (NASDAQ: TSVT) had its "sell (e+)" rating re-affirmed by analysts at Weiss Ratings.
2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVT
2seventy bio, Inc. (NASDAQ: TSVT) had its price target lowered by analysts at Morgan Stanley from $6.00 to $5.00. They now have an "equal weight" rating on the stock.